Wright, Tornier merger completes; NovoCure kicks IPO investor shares out, reduces to $176M;

@FierceMedDev: From FierceDrugDelivery: Intarcia buys Phoundry in search of additional diabetes drugs for its subdermal drug pump. Story | Follow @FierceMedDev

@VarunSaxena2: Study: Oraya radiation tech reduces need for eye injections in AMD patients. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: New Hampshire AG launches investigation into opioid marketing. Article | Follow @EmilyWFierce

> The Wright and Tornier merger has completed after they finalized a deal with the U.S. Federal Trade Commission (FTC). The resulting company will be known as the Wright Medical Group ($WMGI). More

> NovoCure slashed its IPO plans by kicking out existing investors who hoped to sell in the financing. It had intended to sell 7.5 million shares from the company in addition to another 5 million from existing investors, now it will only sell the former. That drops the total raised to $176 million at its existing share price range of $26 to $29. More

> Former head of healthcare for GE Ventures and GE Equity Rafael Torres has joined Varian Medical Systems ($VAR) as its SVP for business development and strategy. More

> Google Life Sciences and the Icahn School of Medicine at Mount Sinai have established a partnership that includes a two-year fellowship at GLS. More

Biotech News

@FierceBiotech: Fierce's coverage of the Martin Shkreli saga. More | Follow @FierceBiotech

@JohnCFierce: Ladies and gentlemen, the 2015 Fierce 15. Special report | Follow @JohnCFierce

> Sarepta gets creative in bolstering its case for quick eteplirsen approval. Report

> Genentech embraces Arvinas with $300M tie-up on protein degradation. Story

> Facing a crisis, Xoma buys time with a $517M Novartis deal. Article

Pharma News

@FiercePharma: Sun Pharmaceutical's Shanghvi drops from top spot in Forbes India rich list. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Merck KGaA counts on Latin America to power consumer-health future. Article | Follow @CarlyHFierce

> Express Scripts: Strict prior-auth moves keep a tight lid on PCSK9 sales. Story

> Novartis stacks up more data for lucrative Cosentyx expansion. Article

Vaccines News

> Novavax's RSV jab protects infants in PhII, nets $89M Gates Foundation grant. Article

> Advaxis targets HER2 cancers with first-in-human vaccine trial. Story

> BiondVax, EU's UNISEC team up for universal flu jab PhIIb. More

> PRA Health joins with clinical research network to improve vaccine studies. Item

> NewLink wins $26.1M in government funding to advance Ebola vaccine. Report

CRO News

> Frontage doubles its bioanalytics space. Item

> Accelovance snags another Big Pharma cancer vet to boost its onco profile. Report

> PRA partners up to accelerate vaccine R&D. More

> Patheon rebrands with a $100M IPO in the works. Story

> Chiltern expands in diabetes after a big buyout. Article

Pharma Manufacturing News

> Siegfried completes $302M deal for BASF API plants. News

> EPA presents Pfizer with $194M bill to cleanup former American Cyanide site. Report

> Abbott said to expand manufacturing, other operations in India. Story

> Will a desktop device that synthesizes lidocaine revolutionize pharma manufacturing? More

> Hovione set to expand its NJ facility and add new spray dryer. Article

Pharma Asia News

> China slaps Fosun Pharma unit with small fine for anti-monopoly violations. News

> Singapore's Biosensors launches sales of BMX-J stent in key Japan market. More

> Australia's Paranta Biosciences raises A$7M for PhI of cystic fibrosis candidate. Report

> China biotech CARsgen inks deal with Shanghai Cancer Institute on candidate focus. Story

> MSF campaigns at UN summit meeting to ease pressure on India's drug IP policies. Article

Suggested Articles

Smith+Nephew is contracting with the U.K. government to build a new ventilator specifically designed for large-scale production.

NantWorks’ ImmunityBio has begun a supercomputing collaboration with Microsoft to map out the spike protein of the novel coronavirus.

President Emmanuel Ligner talks about finalizing a multibillion-dollar deal while adjusting and responding to the global COVID-19 crisis.